Ocuphire Expands Medical Advisory Board with Seven New KOLs and Strengthens Leadership Team

Sep 29, 2022

Ocuphire Announces Upcoming Presentations at European Forum 2022, [email protected] 2022 and the American Academy of Ophthalmology 2022 Annual Meeting

Sep 15, 2022

Ocuphire Pharma Receives PDUFA Fee Waiver for Nyxol New Drug Application from FDA

Sep 12, 2022

Ocuphire Pharma Announces Last Patient Completes Final Visit in ZETA-1 Phase 2b 24-Week Trial of Oral APX3330 in Diabetic Retinopathy

Sep 8, 2022

Ocuphire Pharma to Present at The H.C. Wainwright 24th Annual Global Investment Conference

Sep 6, 2022

Ocuphire Pharma Announces Financial Results for the Second Quarter 2022 and Provides Corporate Update

Aug 12, 2022

Ocuphire Pharma Announces Upcoming Presentations at Two Conferences in August

Aug 8, 2022

Ocuphire Extends U.S. Patent Protection for Late-Stage Drug Candidate Nyxol® for Reversal of Mydriasis by Five More Years into 2039 with New Patent Issuance

Aug 3, 2022

Ocuphire Announces Late-Breaking Paper for Nyxol for Reversal of Dilation Indication at Annual ASRS Meeting and Five More Presentations at Conferences in July

Jul 7, 2022

Ocuphire Granted New U.S. Patent for Late-Stage Oral Drug Candidate APX3330 for Use in Diabetics and Announces New Peer-Reviewed APX3330 Publication

Jun 29, 2022